WOLVERINE TRADING, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.

Quarter-by-quarter ownership
WOLVERINE TRADING, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q1 2023$1,032
+93.3%
18,402
+82.2%
0.00%
+100.0%
Q4 2022$534
-99.9%
10,100
-53.9%
0.00%
-50.0%
Q3 2022$991,000
+58.1%
21,900
+110.6%
0.00%
Q1 2022$627,000
-72.6%
10,400
-76.3%
0.00%
-100.0%
Q4 2021$2,291,000
+118.4%
43,945
+50.0%
0.00%
+100.0%
Q3 2021$1,049,000
+326.4%
29,290
+372.4%
0.00%
Q2 2021$246,000
-71.3%
6,200
-76.7%
0.00%
-100.0%
Q4 2020$857,000
-40.0%
26,600
-52.5%
0.00%
-50.0%
Q3 2020$1,429,000
-4.7%
55,956
-6.0%
0.00%0.0%
Q2 2020$1,499,000
+87.4%
59,546
+17.7%
0.00%
+33.3%
Q1 2020$800,000
-90.9%
50,600
-80.7%
0.00%
-85.7%
Q4 2019$8,820,000
+1423.3%
262,035
+239.4%
0.02%
+950.0%
Q3 2019$579,000
-59.1%
77,200
-29.3%
0.00%
-60.0%
Q2 2019$1,417,000
-15.9%
109,216
-21.0%
0.01%
-16.7%
Q1 2019$1,685,000
+76.1%
138,300
+62.9%
0.01%
+100.0%
Q4 2018$957,000
-71.9%
84,924
-45.9%
0.00%
-62.5%
Q3 2018$3,405,000
+47.0%
156,902
+42.5%
0.01%
+33.3%
Q2 2018$2,316,0000.0%110,0690.0%0.01%0.0%
Q1 2018$2,316,000
+149.8%
110,069
+71.9%
0.01%
+50.0%
Q4 2017$927,000
+8.0%
64,014
+17.7%
0.00%0.0%
Q3 2017$858,000
+115.0%
54,400
+72.7%
0.00%
+100.0%
Q2 2017$399,000
-51.9%
31,500
-38.2%
0.00%
-50.0%
Q1 2017$829,000
+25.8%
51,000
+16.7%
0.00%
+33.3%
Q4 2016$659,000
-66.4%
43,700
-65.7%
0.00%
-66.7%
Q3 2016$1,963,000
-37.7%
127,306
+51.2%
0.01%
-47.1%
Q2 2016$3,152,00084,2000.02%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders